The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a substantial CAGR during the forecast period. Immunotherapy’s recent application in clinical oncology has changed the way we treat advanced human tumors. Immunotherapeutic drugs targeting the CTLA4 and PD-1/PD-L1 axis are currently available to treat a range of malignancies. However, to further improve patient outcomes with these medications, a unique treatment approach is required. indoleamine 2,3-dioxygenase 1 (IDO1) is a rate-limiting enzyme in the peripheral tissue metabolism of the essential amino acid tryptophan.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/indoleamine-2-3-dioxygenase-1-market
In human cancer cells, IDO1 is overexpressed, suppressing effector T cell function while promoting regulatory T cells (Tregs). In different kinds of human cancer, IDO1 overexpression is linked to poor patient survival. These data suggest that IDO1 is a viable target in the field of immuno-oncology, with the potential to improve therapy outcomes. In the last few years, many orally accessible IDO1 inhibitors, notably Epacadostat, have entered human clinical trials with no notable safety concerns. PD-1 inhibitors in combination appear to be more effective than PD-1 inhibitors alone, notwithstanding the lack of objective response in single-agent trials. In the recent phase III ECHO 301 study in melanoma, the combination of Epacadostat with Pembrolizumab did not show a better outcome than Pembrolizumab alone. Other phases III trials involving IDO1 inhibitors were halted as a result of this.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Bristol-Myers Squibb, Merck KGaA, BirchBioMed Inc., Genentech Inc., F. Hoffmann-La Roche Ltd., and others.
Key questions addressed by the report
- What is the market growth rate?
- That segment and region dominate the market in the base year?
- That segment and region will project the fastest growth in the market?
- How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Indoleamine 2,3 Dioxygenase 1 Market Report by Segment
By Type
- BMS-986205
- Dcellvax
- Epacadostat
- F-001287
- Galanal
- Others
By Application
- Alopecia
- Cervical Cancer
- Gastric Cancer
- Glioma
- Others
A full report of Indoleamine 2,3 Dioxygenase 1 Market is available at: https://www.omrglobal.com/industry-reports/indoleamine-2-3-dioxygenase-1-market
Indoleamine 2,3 Dioxygenase 1 Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Globavir Biosciences Inc.
- Incyte Corp.
- IO Biotech
- Kyowa Kirin Co., Ltd.
- Netherlands Translational Research Center B.V. (NTRC)
- NewLink Genetics Corporation (NewLink Genetics)
- Pfizer, Inc.
- Redx Pharma Plc
- Regen biopharma Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
